Open AccessA short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool
Author(s) -
Nahid Eskandari,
Omid Mirmosayyeb,
Gazaleh Bordbari,
Reza Bastan,
Zahra Yousefi,
Alireza Andalib
Publication year - 2015
Publication title -
journal of research in pharmacy practice
Language(s) - English
Resource type - Journals
eISSN - 2319-9644
pISSN - 2279-042X
DOI - 10.4103/2279-042x.167043
Subject(s) - phosphodiesterase , medicine , cyclic nucleotide , cyclic adenosine monophosphate , rheumatoid arthritis , intracellular , adenosine , cyclic guanosine monophosphate , guanosine , nucleotide , gene isoform , cyclic nucleotide phosphodiesterase , pharmacology , enzyme , biochemistry , chemistry , receptor , nitric oxide , gene
Cyclic nucleotide phosphodiesterases (PDEs) are known as a super-family of enzymes which catalyze the metabolism of the intracellular cyclic nucleotides, cyclic-3',5'-adenosine monophosphate (cAMP), and cyclic-3',5'-guanosine monophosphate that are expressed in a variety of cell types that can exert various functions based on their cells distribution. The PDE4 family has been the focus of vast research efforts over recent years because this family is considered as a prime target for therapeutic intervention in a number of inflammatory diseases such as asthma, chronic obstructive pulmonary disease, and rheumatoid arthritis, and it should be used and researched by pharmacists. This is because the major isoform of PDE that regulates inflammatory cell activity is the cAMP-specific PDE, PDE4. This review discusses the relationship between PDE4 and its inhibitor drugs based on structures, cells distribution, and pharmacological properties of PDE4 which can be informative for all pharmacy specialists.